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Introduction
Worldwide, coronary artery disease (CAD) is the single most frequent cause of death (Steg et al., 2012) . In Europe, the annual incidence of hospital admissions due to ST segment elevation acute myocardial infarction (STEMI) is estimated to be approximately 66 per 100 000 inhabitants and mortality rates caused by STEMI remain substantial (approximately 13.5% in-hospital mortality rate and 12% 6-month mortality rate) ( Additionally, high-risk patients, such as diabetics, present a significantly higher mortality rate than those without diabetes (Donahoe et al., 2007) . Indeed, type 2 diabetes mellitus (DM) is associated with increased risk of atherosclerotic disease and poor outcome after an acute myocardial infarction (AMI) (Donahoe et al., 2007) . Nearly 50% of diabetic patients die from cardiovascular disease, establishing it as the leading cause of death among this growing population and contributing to a shortening of average life span by 5-10 years in diabetic patients (Morrish et al., 2001 ).
Endothelial progenitor cells (EPCs) are bone-marrow derived cells that are able to proliferate and differentiate into functionally mature endothelial cells, playing therefore an important role in the regeneration of ischemic tissue and in the maintenance of endothelium integrity (Takahashi et al., 1999) . The number of circulating EPCs increases after AMI, revealing the importance of EPCsmediated tissue and vessel repair as a "physiological" response of the organism to severe ischemia As diabetic patients have a severely impaired endogenous pool of EPCs and no studies have yet been performed examining the direct effects of statins on EPCs isolated from diabetic patients with AMI, it is not known whether EPCs from diabetic patients are still responsive to statins stimulation.
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Therefore, in this study we evaluate the in vitro effects of atorvastatin and pravastatin on functional parameters of early and late EPCs derived from diabetic patients with STEMI and compared them to those obtained from equivalent EPCs from non-diabetic patients. Additionally, to simulate clinical hyperglycemia, we study the effects of high glucose concentration on functional parameters of diabetic and non-diabetic derived EPCs in vitro.
Materials and methods

Study population
A prospective observational study was performed on 20 consecutive patients (10 diabetic and 10 nondiabetic patients) admitted in a single Coronary Care Unit (CCU) due to STEMI, between January 2012 and January 2013. The study was approved by the local ethics committee (project identification code: HUC-23-08). All patients gave written informed consent and research was conducted according to the principles outlined in the Declaration of Helsinki.
Patient inclusion criteria included: age from 40-70 years old, presentation to the cardiac catheterization laboratory for percutaneous coronary intervention (PCI) in the setting of STEMI within 12 h of presentation and no previous treatment with a HMG-Co-A reductase inhibitor in the last 3 months.
Furthermore, only male patients were included in the study, in order to exclude the possible confounding factor of estrogens in women. Patient exclusion criteria included: active infections, clinical or biochemical evidence for the presence of concomitant overt inflammatory disease (highsensitivity C-reactive protein > 10 mg/dl), regular use of non-steroidal anti-inflammatory drugs or anticoagulants, known auto-immune or malignant diseases, severe peripheral arterial occlusive disease, deep vein thrombosis or pulmonary embolism, patients with pacemakers, implantable cardioverter defibrillators or resynchronization devices, atrial fibrillation, recent trauma or surgery (< 1 month), recent major bleeding requiring blood transfusion (< 6 months), renal insufficiency (creatinine > 2.0 mg/dl), anemia (hemoglobin < 8.5g/dl) or thrombocytopenia (< 100 000/l), previous coronary bypass surgery, myocardial infarction within the preceding 2 months, cardiogenic shock, severe valvular disease or congenital heart disease, co-morbidities associated with a life expectancy less than 2 years and excessive alcohol consumption or illicit drugs abuse that may influence EPC kinetics. Diabetic patients already treated with insulin were also excluded. For each non-insulin treated diabetic patient with STEMI we included an age-matched non-diabetic patient.
All patients received the standard therapy for the acute phase of STEMI that included aspirin, clopidogrel and low-molecular-weight heparin, according to usual hospital practice.
On the first morning after admission, blood samples were collected from each patient for chemistry (including fasting glucose and glycosylated hemoglobin (HbA1C)) and hematological parameters determination, according to standard hospital practice.
EPCs isolation and culture
Mononuclear cells (MNCs) were isolated from 20 ml of peripheral blood, by density gradient centrifugation using Ficoll (Histopaque 1077, Sigma-Aldrich), following manufacturer's instructions.
Total MNCs from each patient were cultured according to 2 different protocols to obtain early and late EPCs (see below). For each EPC culture protocol, cells were cultured under four different conditions set from the time of cell plating: 1) Control: normal glucose concentration (5.5 mM); 2) High glucose concentration (25 mM); 3) Incubation in the presence of atorvastatin (0.1 µM) and normal glucose concentration and 4) Incubation in the presence of pravastatin (10 mM) and normal glucose concentration. Statins or high glucose concentration were added at the time of isolation (day 0) and then every time the medium was changed. All experiments were performed on day 7 or day 15 for early or late EPCs, respectively.
Early EPCs
Immediately after isolation, 5x10 6 MNCs were resuspended in 1.5 ml of endothelial basal medium (EBM-2, Clonetics) supplemented with EGM-2-MV-SingleQuots (Clonetics) containing hydrocortisone, human fibroblast growth factor-B (hFGF-B), vascular endothelial growth factor (VEGF), human recombinant Insulin-like growth factor-1 (R3-IGF-1), ascorbic acid, human recombinant epidermal growth factor (hEGF), gentamicin/ amphotericin B, and 20% fetal bovine serum. Cells were plated on fibronectin-coated 6-well dishes (Biocoat BD) at 37°C in a 5% CO 2 incubator. After a 48 h pre-plating step to deplete the sample of adherent macrophages and mature endothelial cells, the non-adherent cells were collected, and re-plated at a density of 1x10 6 
In vitro studies on the effects of statins and high glucose concentration on cultured early and late EPCs
The effects of high glucose concentration, atorvastatin and pravastatin on proliferation, viability, survival, and expression of typical cell surface markers were assessed in cultured EPCs derived from diabetic and non-diabetic patients with STEMI following the protocols below:
Analysis of early EPCs proliferation -EPC colony-forming units (CFU) assay
Early EPCs proliferation was assessed by the number of colony-forming units, after 7 days in culture as described by Hill and colleagues (Hill et al., 2003 ). An EPC colony was defined as a central core of at least 50 round cells with radiating elongated spindle-like cells at the periphery. A central cluster alone without associated emerging cells was not counted as a colony. Two independent investigators under blind condition counted all colonies in each well, manually using a phase-contrast microscope at ×100 magnification, to obtain the average number of colonies per well.
Viability and survival evaluation
Viability of early EPCs was studied using trypan blue staining after 7 days in culture. Cultured cells from each condition were trypsinized (trypsin-EDTA 0.25%, Sigma) and the number of viable cells was counted using a hemacytometer.
Late EPCs derived from 5x10 6 MNCs per well were quantified by direct counting, every 3 days starting from day 6 (the day of the second medium change) to day 15, and calculation of the average number of cells present in 10 randomly selected high-power fields, under a phase-contrast microscope.
For this quantification ImageJ 1.45 s software (National Institutes of Health, USA) was used and survival curves created. Data are expressed as the number of cells per high-power field. At day 15, late EPCs were released from the original culture plates by trypsinization, stained with trypan blue and 8 counted using a hemacytometer.
Cell cycle analysis of late EPCs by flow cytometry -DRAQ5
Cell cycle analysis was assessed by DRAQ5 (Biostatus Ltd., Leicesterchire, UK) staining and flow cytometry evaluation. DRAQ5 specifically binds to DNA by rapidly penetrating intact cell membranes.
At day 15, 3x10 5 cells in 250 µl of PBS, previously stained for surface antigens were incubated with 2 µl of DRAQ5 for 5 min at room temperature and protected from bright light. Samples were acquired on a FACSCanto II flow cytometer (BDBiosciences). The ModFit LT™ 4.0 software (Verity Software
House, Topsham, ME) was used to evaluate the proportion of late EPCs in S-phase (DNA Synthesis Phase).
Expression of CD34, CD133, KDR and CXCR4
Early and late EPCs were trypsinized, after 7 or 15 days in culture, respectively and analysed by flow cytometry to compare the expression of different cell surface markers (CD34, CD133, KDR and CXCR4), measured as mean fluorescence intensity (MFI).
Statistical Analysis
Statistical analyses were performed using SPSS software version 20.
Continuous variables were tested for normal distribution by Kolmogorov-Smirnov test and expressed as mean ± standard deviation or median ± interquartile range for parametric and nonparametric data, respectively. Categorical data is expressed as counts and percentages. 
Results
Patient characteristics
Comparison of the baseline characteristics of diabetic versus non-diabetic STEMI patients is summarized in Table 1 .
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The two groups were relatively homogenous in terms of age, cardiovascular risk factors and previous history of coronary artery disease (CAD). However, diabetic patients tended to be more frequently treated with ACE inhibitors/AT-1 receptor blockers and presented, as expected, significantly higher admission glycemia, fasting glycemia and HbA1c levels when compared with non-diabetic patients. In the diabetic group, the duration of diabetes varied from 3-13 years (mean 6.5 ± 3.1 years).
All 20 patients included in this study underwent successful revascularization with deployment of at least one stent.
Characterization of cultured EPCs
Both early and late EPCs displayed a characteristic EPC phenotype as judged by by dil-acLDL uptake, UEA-1 binding and expression of CD34 and VEGFR2 on the plasma membrane. Early EPCs, but not late EPCs, also expressed CD133, a marker for more immature cells. Co-staining with the nuclear marker DAPI revealed that virtually all adherent cells were dil-acLDL(+) UEA-1(+) ( Fig. 1 -A Flow cytometry analysis demonstrated that the majority of early and late cultured EPCs exhibited lightscattering properties consistent with a relatively large cell size. Additionally, this analysis revealed that early and late EPCs were positive for KDR, CD34 and CXCR4, confirming their endothelial phenotype. As expected, only early EPCs expressed the myeloid marker CD45 and the marker for immaturity/stemness CD133.
Effect of statins and high glucose concentration on CFUs
After 5 to 7 days in culture, attached cells exhibited typical colony-forming units, with a characteristic central cluster of round cells and peripheral radiating flat cells ( Fig. 1-C) . These cells showed the characteristic Dil-Ac-LDL uptake and UEA-1 lectin binding.
Under control conditions, the number of cell colonies generated from 5x10 6 MNCs was 2.1 ± 1.2/well and incubation in high-glucose (25 mmol/l) resulted in diminished CFU formation (31% inhibition, P<0.05); in contrast, the number of colonies resulting from incubation with atorvastatin (3.9±1.8) or pravastatin (4.2±2.9) was significantly higher when compared to untreated cells (P<0.001), corresponding to a 1.9 to 2-fold increase in colony formation when compared to control conditions (Fig. 2) .
Under control conditions, CFU numbers were significantly reduced in cells derived from diabetic patients when compared to equivalent cells obtained from non-diabetic patients (1.4±0.8 versus 2.6±1.2 CFU/well, P=0.021) (Fig. 3) . When cells of non-diabetic patients were grown in high glucose, CFU capacity was significantly reduced reaching similar numbers to those observed for cells derived from diabetic patients under control conditions (1.6±0.7 versus 1.4±0.8 CFU/well, respectively, P=0.631) (Fig. 3) . Finally, treatment of early EPCs from diabetic patients with 0.1 µM atorvastatin or 10 mM pravastatin resulted in increased CFU values, surpassing CFU capacity of early EPCs from nondiabetic patients under control conditions (Fig. 3) . 
Effect of statins on EPCs survival and viability
Early EPCs
Late EPCs
The survival curve of late EPCs showed a general downward trend, in all conditions tested. As shown in Fig. 4 , statin treatment seems to delay the onset of late EPCs senescence. Moreover, this delay was verified not only in cells from non-diabetic but also in those from diabetic patients. However, survival at the later stage of culture was not affected by statin supplementation; at day 15 no significant differences were observed in the numbers of viable cells amongst the different study conditions.
Additionally, no significant differences were found between the diabetic and non-diabetic subgroups 
Cell cycle analysis of late EPCs by flow cytometry -DRAQ5
As atorvastatin seemed to delay senescence onset, we examined whether that was accompanied by an increase in cell proliferation by determining the proportion of late EPCs in S-phase of the cell cycle at the end of culture time.
As shown by FACS analysis of DRAQ5 labelling, statin treatment induced nearly a 2-fold increase in the proportion of cells in S-phase when compared to control conditions (atorvastatin: 13.8±4.5%; control: 7.9±3.3%, p=0.048 and pravastatin: 15.7±1.1%; control: 7.9±3.3%, P=0.025) (Fig. 5 -A) .
Additionally, cells from diabetic patients under control conditions showed a significantly reduced proportion of late EPCs in S-phase at day 15 (diabetics: 9.4±4.0%; non-diabetics: 21.9±6.0%, P=0.026)
( Fig. 5-B ).
Expression of cell surface markers assessed by FACS (mean fluorescence intensity)
Mean fluorescence intensities (MFI) for cell surface expression of the characteristic markers CD34, KDR and CXCR4 were assessed for early and late EPCs by flow cytometry. MFI for CD133 was also determined for early EPCs. CD34 and CXCR4, P=0.007 and P=0.008, respectively and 26% increase for KDR, P=0.024) (Fig. 6 -B ).
Comparison of MFI for marker expression in late EPCs from diabetic versus non-diabetic patients revealed different patterns. Thus, KDR expression was significantly lower in cells from diabetic patients compared to those of non-diabetic patients, when cells were cultured in either control or high glucose conditions; showing the same tendency when the medium was supplemented with atorvastatin or pravastatin (Fig. 7) . CD34 expression was also significantly reduced in late EPCs from diabetics when compared to those from non-diabetics, when cultured under high glucose conditions; and showed the same trend down for the other 3 culture conditions (Fig. 7) . Finally, expression of the homing marker CXCR4 showed no differences between cells derived from non-diabetic or diabetic patients under any of the culture conditions tested.
Discussion
The major finding of this study is the demonstration that statins have a favorable effect on functional The present study has shown that DM has a significant negative impact on several functional parameters of both types of EPCs in vitro. When compared to the non-diabetic subgroup under the same conditions, cells from diabetic patients show: 1) diminished CFU capacity in early EPCs; 2) attenuated expression of the endothelial marker KDR and of the hematopoietic progenitor marker CD34 in late EPCs (however, no differences were observed in the expression of the homing marker, CXCR4); and 3) reduced proportion of late EPCs in S-phase at the end of culture time. However, no differences were observed in the survival rates of either early or late EPCs between the two patient subgroups. Taken together, these data suggest that the functional impairment of EPCs in diabetic patients might be mainly due to problems related to their proliferative capacity, as judged by a reduction in CFU capacity for early EPCs and lower proportion of late EPCs in S-phase. CXCR4, the receptor for stromal cell-derived factor-1 (SDF-1), is highly expressed on EPCs and plays a pivotal role in their homing to ischemic sites (Mohle et al., 1998 Importantly, in this study, we have shown for the first time that by culturing EPCs from non-diabetic AMI patients in experimental hyperglycemic-like conditions we were able to induce EPCs dysfunction, such as reduction in CFU formation, to equivalent levels of early EPCs from diabetic patients under normal glucose conditions. In addition, despite the expression levels of the homing marker CXCR4
being similar in late EPCs from diabetic and non-diabetic patients under normal glucose conditions, long-term exposure of late EPCs to high glucose resulted in a markedly reduction of its expression.
These data suggest therefore, that hyperglycemia per se, could at least in part, be responsible for EPC dysfunction seen in diabetes. limitations, including the fact that CFU could not be measured in all patients and that the statin group exhibited a more severe degree of CAD and had a higher prevalence of diabetes that might have biased the results. Furthermore, it is worth noting that in the study performed by Hristov et al statins were administered to patients, whereas in the present study atorvastatin and simvastatin were tested in vitro.
Given the ability to precisely control testing conditions and the absence of potential environment factors interfering with statins actions, the direct exposure of EPCs to statins in vitro had the advantage to specifically identify the effects of statins on EPCs. Importantly, with in vitro assays we overcome the problem of potential interference of other cardiovascular drugs commonly used in these patients.
Furthermore, we were able to evaluate at the same time two different statins.
No previous published studies have analyzed the effects of statins on EPC function from diabetic patients, with an AMI. Therefore, we tested the hypothesis that, despite their profound endogenous dysfunction, early and late EPCs from diabetic patients are still responsive to statins.
In the present study, we have shown that in vitro exposure of early and late EPCs from STEMI patients to atorvastatin or pravastatin results in remarkably improved cellular proliferation, with the CFU capacity and the proportion of late EPCs in the proliferative stage doubling in number when compared to values obtained under control conditions. Notably, this statin-mediated effect was also verified in cells from diabetic patients, with resulting CFU capacity surpassing that observed in EPCs from nondiabetic patients grown in normal control conditions. Furthermore, statin treatment was also able to improve the viability of early EPCs and delay the onset of late EPCs senescence, in both non-diabetic and diabetic patients. Altogether, these data provide strong evidence that statins consistently improve 2) our data also provide a rationale for the early statin administration in AMI patients, including those with diabetes; 3) enhancement of endothelial repair with cell-based therapies, during the in vivo response to ischemia, may become a realistic clinical goal, once EPC dysfunction associated with diabetes is pharmacologically reverted.
Study limitations
This study has some inherent limitations that should be considered. First, the study population is relatively small. These data, however, are based on a careful selection of patients, including only statin naïve men with STEMI, thus limiting the recruitment of large numbers of patients. Indeed, it should be noted that each diabetic patient was individually age-matched with a non-diabetic patient and each patient served as his own control, 
Conclusions
In summary, this study provides the first evidence that statins can improve EPCs dysfunction of diabetic patients with STEMI comparable to what is seen in non-diabetic patients. Statin therapy may represent an important strategy to acutely improve vascular repair and, thereby, offer a therapeutic opportunity to improve prognosis of diabetic patients with AMI.
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